# 02/07/01

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. 13388

Total Pages in this Submission

(Only for new nonprovisional applications under 37 CFR 1.53(b))

#### TO THE ASSISTANT COMMISSIONER FOR PATENTS **Box Patent Application** Washington, D.C. 20231 Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled: BIOMOLECULAR TOXICITY ASSAY and invented by: Cristobal Guillermo dos Remedios Murat Kekic Arthur Roger Cooke If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: ₩Vnich is a: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Which is a: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Enclosed are: **Application Elements** Filing fee as calculated and transmitted as described below pages and including the following: 28 2. Specification having Descriptive Title of the Invention a. 🗶 b. Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) C. 🗌 Reference to Microfiche Appendix (if applicable) d. 🔲 Background of the Invention e. 🗷 Brief Summary of the Invention f. 🗶 Brief Description of the Drawings (if drawings filed) X **Detailed Description** h. 🔀 X Claim(s) as Classified Below j. X Abstract of the Disclosure

### **UTILITY PATENT APPLICATION TRANSMITTAL** (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13388

Total Pages in this Submission

#### **Application Elements (Continued)**

3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)
	a.	☐ Formal b. ⊠ Informal Number of Sheets1
4.		Oath or Declaration
	a.	☐ Newly executed (original or copy) ☐ Unexecuted
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
	C.	☐ With Power of Attorney ☐ Without Power of Attorney
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6.		Computer Program in Microfiche
7.		Genetic Sequence Submission (if applicable, all must be included)
	a.	☐ Paper Copy
	b.	☐ Computer Readable Copy
~	C.	☐ Statement Verifying Identical Paper and Computer Readable Copy
		Accompanying Application Parts
8.		Assignment Papers (cover sheet & documents)
9.		37 CFR 3.73(b) Statement (when there is an assignee)
10.		English Translation Document (if applicable)
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations
12.	X	Preliminary Amendment
13.	X	Acknowledgment postcard
14.	X	Certificate of Mailing
		☐ First Class ► Express Mail (Specify Label No.): EL739620715US

### UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13388

Total Pages in this Submission

		Accompanying Application Parts (Continued)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
165	15.	Small Entity Statement(s) - Specify Number of Statements Submitted:  Small Entity Status is entitled to be asserted in respect to the Additional Enclosures (please identify below):
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 13388

Total Pages in this Submission

#### Fee Calculation and Transmittal

			CLAIMS A	AS FILED			
For	#Filed		#Allowed	#Extra		Rate	Fee
Fotal Claims	33	*	- 20 =	13	х	\$9.00	\$117.00
ndep. Claims	4	*	- 3 =	1	х	\$40.00	\$40.00
ਹੈ Multiple Dependent (	Claims (che	ck if	applicable)				\$0.00
* Claims ca	lculated	d ba	ased on Pr		У	BASI	C FEE \$355.00
Amendment OTHER FEE (specify		ner	ewith.				\$0.00
						TOTAL FILIN	G FEE \$512.00

X	A check	in the amount of	\$512.00	to cover the filing fee is enclosed.	
X	The Co	mmissioner is hereby	authorized to	charge and credit Deposit Account No.	19-1013/SSMP
		cribed below. A duplic			
		Charge the amount of	of	as filing fee.	
	X	Credit any overpaym	ent.		
	X	Charge any additiona	al filing fees r	required under 37 C.F.R. 1.16 and 1.17.	
		Charge the issue fee	set in 37 C.F	F.R. 1.18 at the mailing of the Notice of A	llowance,

Dated: February 7, 2001

pursuant to 37 C.F.R. 1.311(b).

Frank S. DiGiglio Registration No.: 31,346

SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516)742-4343

CC:

	MAILING BY "EXPRESS I Guillermo dos Remedios, et al.	MAIL" (37 CFR 1.10)	Docket No.
			13388
Serial No.	Filing Date	Examiner	Group Art Unit
Unassigned	Herewith	Unassigned	Unassigned
vention: <b>BIOMOLE</b>	ULAR TOXICITY ASSAY		<u> </u>
I hereby certify that the	e following correspondence:		
New Patent Application	1		
	(Identify type	f correspondence)	
is being deposited with	the United States Postal Servi	ce "Express Mail Post Office to A	ddressee" service under
07 OFD 4 40 to a second	along additioned to The Apple	lant Onemalaria and for Detaute 1	Markinston D.O. 00004
	-	tant Commissioner for Patents, \	wasnington, D.C. 20231
February (Date)			
		Janet Giordan	
		Janet Giorgan	0
		(Typed or Printed Name of Person Mail.	
			ing Correspondence)
		(Typed or Printed Name of Person Mail	ing Correspondence)  1. Orrespondence)
		(Typed or Printed Name of Person Mail  (Signature of Person Mailing Con	ing Correspondence) Tespondence)
		(Typed or Printed Name of Person Mail.  (Signature of Person Mailing Con	ing Correspondence) Tespondence)
		(Typed or Printed Name of Person Mail.  (Signature of Person Mailing Con	ing Correspondence) Tespondence)
		(Typed or Printed Name of Person Mail  (Signature of Person Mailing Con  EL739620715U  ("Express Mail" Mailing Labo	ing Correspondence) Tespondence)
	Note: Each paper must ha	(Typed or Printed Name of Person Mail.  (Signature of Person Mailing Con	ing Correspondence) Tespondence)
	Note: Each paper must ha	(Typed or Printed Name of Person Mail  (Signature of Person Mailing Con  EL739620715U  ("Express Mail" Mailing Labo	ing Correspondence) Tespondence)
	Note: Each paper must ha	(Typed or Printed Name of Person Mail  (Signature of Person Mailing Con  EL739620715U  ("Express Mail" Mailing Labo	ing Correspondence) Tespondence)
	Note: Each paper must ha	(Typed or Printed Name of Person Mail  (Signature of Person Mailing Con  EL739620715U  ("Express Mail" Mailing Labo	ing Correspondence) Tespondence)